Jacobio Pharmaceuticals Group Co., Ltd.
HKSE: 1167.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yinxiang Wang
- Employees
- 257
- Headquarters
- Beijing, China
- IPO year
- 2020
- Market cap
- HK$4.9B
- Website
- https://www.jacobiopharma.com
Loading 1167…
Loading profile data…Frequently asked questions about 1167
What does Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) do?
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the t...
Where does 1167.HK trade?
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) trades on the Hong Kong Stock Exchange.
What sector is 1167.HK in?
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jacobio Pharmaceuticals Group Co., Ltd.?
Yinxiang Wang is the chief executive officer of Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK).
Where is Jacobio Pharmaceuticals Group Co., Ltd. headquartered?
Jacobio Pharmaceuticals Group Co., Ltd. is headquartered in China.
Does 1167.HK pay a dividend?
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1167.HK go public?
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) completed its initial public offering in 2020.